Nasdaq:US$15.16 (+0.08) | HKEX:HK$23.05 (-0.45) | AIM:£2.25 (+0)
Search
Announcements
12345678
9
1011121314151617
found Documents: 833
Announcements & Press Releases, Regulatory Notice | 3 Oct 2019

TR-1: Form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hutch
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 30 Sep 2019

CK Hutchison prices offering of Chi-Med share capital enabling deconsolidation and confirms its intention to hold Chi-Med as a strategic investment for the long term
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   London: Monday, September 30, 2019: Hutchison Chin
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 30 Sep 2019

CK Hutchison offers 1.3% of Chi-Med’s share capital aiming to deconsolidate and hold Chi-Med as a strategic investment for the long term
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   London: Monday, September 30, 2019: Hutchison Chin
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 30 Sep 2019

Total Voting Rights
London: Monday, September 30, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at September 30, 2019, the issued share capital of Chi-Med consisted of 666,786,450 ordinary shares of US$0.10 e
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 Sep 2019

Chi-Med to Discuss Surufatinib Phase III and U.S. Phase I/Ib Efficacy and Safety Data Presented at the 2019 ESMO Annual Meeting
Press Release – Surufatinib achieved primary endpoint, reducing the risk of progression or death by 67% in patients with non-pancreatic neuroendocrine tumors (“NET”) in the Phase III SANET-ep study – – Preparations underway for the potent
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 25 Sep 2019

Chi-Med Highlights Presentation of Clinical Data from the Successful SANET-ep Phase III Trial at ESMO Annual Meeting
– Late-Breaking Abstract of the positive SANET-ep Phase III trial of surufatinib in patients with non-pancreatic neuroendocrine tumors (“NET”) to be presented – – Conference call and webcast with lead trial investigators to be held on Mond
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 18 Sep 2019

Chi-Med Highlights Oral Presentations at 2019 CSCO Annual Meeting
London: Wednesday, September 18, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) shares additional analyses from three completed and ongoing clinical studies of fruquintinib and savolitinib at the 22nd Annual Meeting of the C
Read More
Download Press Release (PDF)
Announcements & Press Releases, Group, Press Releases | 3 Sep 2019

Chi-Med to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference
London: Tuesday, September 3, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will participate in a fireside chat at Morgan Stanley 17th Annual Global Healthcare C
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 3 Sep 2019

Chi-Med Initiates an International Phase I/Ib Trial of HMPL-689 in Patients with Advanced Relapsed or Refractory Lymphoma
London: Tuesday, September 3, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated an international Phase I/Ib study of HMPL-689, its novel, highly selective and potent small molecule phosphoinositide-3 kinase delta
Read More
Download Press Release (PDF)
Announcements & Press Releases, Regulatory Notice | 30 Aug 2019

Total Voting Rights
London: Friday, August 30, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at August 30, 2019, the issued share capital of Chi-Med consisted of 666,777,450 ordinary shares of US$0.10 each, w
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 23 Aug 2019

Chi-Med Initiates a Phase I Trial of HMPL-523 in Patients with Immune Thrombocytopenia (ITP) in China
London: Friday, August 23, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase I study of HMPL-523, its novel spleen tyrosine kinase (“Syk”) inhibitor, in patients with immune thrombocytopenia (“ITP”
Read More
Download Press Release (PDF)
Announcements & Press Releases, Regulatory Notice | 20 Aug 2019

TR-1: Form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hut
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 30 Jul 2019

TR-1: Form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hut
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 30 Jul 2019

Chi-Med Reports 2019 Interim Results and Provides Updates on Key Clinical Programs
London: Tuesday, July 30, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces its unaudited financial results for the six months ended June 30, 2019 and provides updates on key clinical programs.  Major highlight
Read More
Download Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 3 Jul 2019

TR-1: Form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hutch
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 3 Jul 2019

TR-1: Form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hut
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 3 Jul 2019

Chi-Med to Announce 2019 Half-Year Financial Results
London: Wednesday, July 3, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2019 on Tuesday, July 30, 2019 at 7:00 am British Summer Time (BST) (2:00 pm
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 28 Jun 2019

Blocklisting Six Monthly Return
London: Friday, June 28, 2019: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return:   1. Name of applicant: Hutchison China MediTech Limite
Read More
Download Announcement (PDF)
Announcements & Press Releases, Group | 28 Jun 2019

Chi-Med Announces Pricing of Upsized U.S. Public Secondary Offering of American Depositary Shares
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: June 28, 2019: Hutchison China MediTech Limited (“
Read More
Download Announcement (PDF)
Announcements & Press Releases, Group | 27 Jun 2019

Chi-Med Announces Secondary Offering of American Depositary Shares
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: June 27, 2019: Hutchison China MediTech Limited (“
Read More
Download Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 14 Jun 2019

Chi-Med Announces that Surufatinib Phase III SANET-ep Study Has Met its Primary Endpoint at Interim Analysis in Advanced Non-Pancreatic Neuroendocrine Tumors in China and Will Stop Early
London: Friday, June 14, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that the independent Data Monitoring Committee (“IDMC”) of the Phase III pivotal study of surufatinib in advanced neuroendocrine tum
Read More
Download Press Release (PDF)
Announcements & Press Releases, Regulatory Notice | 12 Jun 2019

Block Admission Applications and Total Voting Rights
London: Wednesday, June 12, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that the following applications have been made to the London Stock Exchange plc for the block admission of ordinary shares, par value
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 6 Jun 2019

Disclosure Update
London: Thursday, June 6, 2019: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) today filed the Post Hearing Information Pack (the “PHIP”) with the Stock Exchange of Hong Kong Limited (“SEHK”) in connec
Read More
Download Announcement (PDF)
Announcements & Press Releases, Group | 29 May 2019

Results of Extraordinary General Meeting
London: Wednesday, May 29, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that the ordinary resolution and special resolution put to its Extraordinary General Meeting (“EGM”) held on May 29, 2019 were dul
Read More
Download Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 22 May 2019

Grant of Share Options under Share Option Scheme
London: Wednesday, May 22, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on May 21, 2019, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meeting
Read More
View Announcement (PDF)
Announcements & Press Releases, Group | 3 May 2019

Notice of Extraordinary General Meeting and Shareholders' Circular
London: Friday, May 3, 2019: Hutchison China MediTech Limited (“Chi-Med” or “Company”) (AIM/Nasdaq: HCM) today announces that an Extraordinary General Meeting (“EGM”) is to be held at 11:00 a.m. London time on Wednesday, May 29, 2019. An
Read More
Download Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 24 Apr 2019

Results of Annual General Meeting
London: Wednesday, April 24, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual General Meeting (“AGM”) held on April 24, 2019 were duly
Read More
Download Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 15 Apr 2019

Disclosure Update
London: Monday, April 15, 2019: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) today filed an application (the “Listing Application”) with the Stock Exchange of Hong Kong Limited (“SEHK”) in connection
Read More
Download Announcement (PDF)
Announcements & Press Releases, Group | 15 Apr 2019

Chi-Med Files Application to List in Hong Kong and Announces Proposed Global Offering
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Hong Kong: Monday, April 15, 2019: Hutchison China MediTech
Read More
Download Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 Mar 2019

Chi-Med Initiates a Phase IIb/III Trial of Surufatinib in Patients with Unresectable or Metastatic Biliary Tract Cancer in China
London: Friday, March 29, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a registration-enabling Phase IIb/III study comparing surufatinib (HMPL-012 or sulfatinib) with capecitabine in patients with advanced
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 28 Mar 2019

Chi-Med Highlights Oral Presentations on Savolitinib Lung Cancer Programs at AACR Annual Meeting
Press Release London: Thursday, March 28, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will share further data on the savolitinib development programs in lung cancer at the American Association of Cancer Research (AACR)
Read More
Download Press Release (PDF)
Announcements & Press Releases, Regulatory Notice | 25 Mar 2019

Vesting of awards under the Long Term Incentive Plan
London: Monday, March 25, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that following the publication of the 2018 annual report of Chi-Med on March 21 2019, the following awards granted under the Long Term Incent
Read More
Download Announcement (PDF)
Announcements & Press Releases, Group | 21 Mar 2019

2018 Annual Report and Notice of Annual General Meeting
London: Thursday, March 21, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that its 2018 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been posted to shareholders
Read More
Download Announcement (PDF)
Announcements & Press Releases, Group | 11 Mar 2019

Publication of Form 20-F
London: Monday, March 11, 2019: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today published the Form 20-F for the financial year ended December 31, 2018. This is available for viewing at http://www.rns-pdf.londonstockexchange.com/r
Read More
View Form 20-F (PDF)
Announcements & Press Releases, Group | 11 Mar 2019

Chi-Med Reports 2018 Full Year Results and Provides Updates on Key Clinical Programs
London: Monday, March 11, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces its audited financial results for the year ended December 31, 2018 and provides updates on key clinical programs. Video webcas
Read More
Download Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 12 Feb 2019

Chi-Med Highlights Preliminary Phase II Savolitinib / Imfinzi® Combination Data in Advanced Papillary Renal Cell Carcinoma at 2019 ASCO Genitourinary Cancers Symposium
London: Tuesday, February 12, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announced the availability of preliminary results from the Phase II CALYPSO study of the savolitinib / Imfinzi® (durvalumab) combination in
Read More
Download Press Release (PDF)
Announcements & Press Releases, Group | 8 Feb 2019

Chi-Med to Announce 2018 Final Results
London: Friday, February 8, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will announce its final results for the year ended December 31, 2018 on Monday, March 11, 2019 at 7:00 am Greenwich Mean Time (GMT). An analyst pr
Read More
Download Announcement (PDF)
Announcements & Press Releases, Group, Press Releases | 7 Jan 2019

Chi-Med to Present at the 37th Annual JP Morgan Healthcare Conference
Press Release London: Monday, January 7, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 37th Annual JP Morgan Healthcare Conference on Wednes
Read More
Download Press Release (PDF)
Announcements & Press Releases, Regulatory Notice | 31 Dec 2018

Blocklisting Six Monthly Return
London: Monday, December 31, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: (
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 31 Dec 2018

Total Voting Rights
London: Monday, December 31, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at December 31, 2018, the issued share capital of Chi-Med consisted of 66,657,745 ordinary shares of US$1.00 each
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 20 Dec 2018

Chi-Med Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company
– Chi-Med acquires right to determine & conduct all future life cycle indication development of fruquintinib monotherapy as well as innovative combinations in China –  – Chi-Med to assume all development costs of life cycle indications in
Read More
Download Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 20 Dec 2018

Chi-Med Announces Progress in Savolitinib Lung Cancer Program and Update on Kidney Cancer Strategy
– Global SAVANNAH study of savolitinib / Tagrisso®combination in MET+ EGFRm NSCLC underway. Data presented at ESMO 2018 showedMET-amplification among the most frequent mechanisms of acquired resistance to AstraZeneca’s Tagrisso® – – China
Read More
Download Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 14 Dec 2018

TR-1: Form for notification of major holdings
Download Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 30 Nov 2018

Total Voting Rights
London: Friday, November 30, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at November 30, 2018, the issued share capital of Chi-Med consisted of 66,623,441 ordinary shares of US$1.00 each
Read More
View Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 Nov 2018

Chi-Med Enters into Multiple Collaborations to Evaluate Combinations of Surufatinib and Fruquintinib with PD-1 Checkpoint Inhibitors
London: Thursday, November 29, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) entered into four collaboration agreements to evaluate the safety, tolerability and efficacy of Chi-Med’s surufatinib (HMPL-012 or sulfatinib) a
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 26 Nov 2018

Chi-Med Announces First Commercial Launch of Fruquintinib Capsules (Elunate®)
London: Monday, November 26, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces the first commercial launch of fruquintinib capsules (Elunate®) with the initiation of product sales in China. Elunate® is for the
Read More
Download Press Release (PDF)
Oncology / Immunology | 20 Nov 2018

Chi-Med Receives BayHelix R&D Achievement of the Year Award at BioCentury China Healthcare Summit
Shanghai: November 20, 2018: Hutchison China MediTech (“Chi-Med”) received “R&D Achievement of the Year” Award from BayHelix at the BioCentury China Healthcare Summit on November 14, 2018. Hutchison MediPharma, the Innovation Platform
Read More
Download Press Release (PDF)
Announcements & Press Releases, Oncology / Immunology | 16 Nov 2018

Chi-Med Announces Phase III FALUCA Trial Results for Fruquintinib in Third-Line, Advanced Non-Small Cell Lung Cancer in China
– Trial did not meet the primary endpoint of overall survival despite improvement in progression-free survival – London: Friday, November 16, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces the outcome of
Read More
View Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 31 Oct 2018

Total Voting Rights
London: Wednesday, October 31, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at October 31, 2018, the issued share capital of Chi-Med consisted of 66,618,660 ordinary shares of US$1.00 eac
Read More
Download Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 22 Oct 2018

Grant of Share Options under Share Option Scheme
London: Monday, October 22, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on October 19, 2018, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Mee
Read More
View Announcement (PDF)
12345678
9
1011121314151617